**Fatal Issues**

The preregistration/frozen-run inconsistency is currently submission-killing. If `EXTERNAL_BENCHMARK_PREREG.md` says DRAFT/not frozen and the repo is not git-tracked, the paper cannot honestly claim NACC/CNP were preregistered frozen run-once evaluations. For a claim-governance paper, provenance integrity is not bookkeeping; it is the central thesis.

The external evidence does not yet support the strongest safety claim. NACC has 0/28 null false confirms, but the upper 95% CI is still 12.3%, missing the stated <10% target, and the AD-spared controls are not clean nulls. CNP shows abstention, but also provides no positive psychiatric confirmation, so it mostly demonstrates low power or conservatism.

**Major Issues**

The headline FCR number is compelling but partly synthetic and internally dominated. Combining 150 generated negatives with 27 main negatives gives 1/177, but reviewers will discount synthetic negatives unless construction is airtight. The one false confirm being “likely misconstructed” is not a defense; it is either a real failure or evidence that the stress suite lacks validity control.

Power gate design is vulnerable: using external `ref_effect` when available but otherwise falling back to observed standardized effect can leak winner’s-curse optimism into admissibility. This needs a much clearer statistical justification or a conservative default.

Coverage is low: 12/40 MAIN claims confirmed. That may be acceptable if framed as a conservative governance layer, but not if the paper implies broad automation of scientific claims.

The multi-LLM result is too small. Verdict agreement 7/9 and numeric guard catching 40 numbers are useful engineering evidence, not robustness evidence.

Related-work risk is real. If NEXUS/NEURA citations are weak, unverifiable, or overstated, the novelty framing becomes fragile.

**Method/Baseline/Novelty Assessment**

The core idea is good: separate agentic drafting from statistical claim admissibility, freeze a ClaimContract, compute all numbers in code, and block unauthorized numeric claims. That is a clean systems contribution for ML-for-health.

The gates are conventional: multiplicity/search provenance, confounds, power, multiverse, and replication are not novel statistically. The novelty is their enforcement as a post-execution governance layer for LLM/agentic neuroimaging, especially the numeric guard and verdict ladder.

The NeuroClaw comparison is the strongest evidence: shared 25 claims, NeuroClaw FCR 5/15 versus CONFIRM 0/15, with TPR preserved or improved. The post-hoc layer result is especially important because it shows CONFIRM can improve an existing agent pipeline rather than requiring a new end-to-end system.

The paper should not oversell “truth.” It should claim controlled admissibility under explicit statistical gates, not scientific correctness.

**Required Fixes Before Submission**

Resolve the preregistration issue completely. Either prove the external runs were frozen with immutable timestamps, hashes, contracts, code, and result manifests, or remove “preregistered/run-once” language and call them external retrospective evaluations.

Replace stale staged indexes with a single auditable result manifest. Every reported number needs a path, hash, cohort, claim ID, and contract version.

Clarify the power gate and remove observed-effect fallback unless justified by simulation or sensitivity analysis.

Separate internal, synthetic, and external FCR claims. Do not blend them into one headline without stratification.

Add exact confidence intervals everywhere FCR is central.

Fix related work citations and explicitly position against NeuroClaw/NeuroAgent/NIAgent as workflow/QC/prediction systems, while CONFIRM is statistical claim governance.

Tone down NACC: it is promising external evidence, not yet a passed preregistered safety benchmark.

**Score/Readiness**

Current readiness: borderline workshop / weak main-conference submission.

WACV/ML-for-health score: **5/10** as submitted. With provenance fixed, cleaner external framing, and stronger auditability, this could become **6.5-7/10**.

Main reason to reject now: the paper’s central claim is governance/provenance, and the external preregistration record appears internally inconsistent. Main reason to keep working: the NeuroClaw delta and full-ladder ablation are genuinely compelling.
